352 results on '"Putignani L."'
Search Results
2. P109 Organic Cation Transporter (OCTN)-1 variants shape innate immunity and predict individual response to vedolizumab In ulcerative colitis patients
3. P1213 The effects of Escherichia coli Nissle 1917 on the gut microbiota composition in ulcerative colitis patients
4. P096 Human extrachromosomal circular DNA is an emerging biomarker in Inflammatory Bowel Disease
5. Nasopharyngeal microbiota in hospitalized children with Bordetella pertussis and Rhinovirus infection
6. T.10.3 THE EFFECT OF VEDOLIZUMAB ON COLONIC MICROBIOTA COMPOSITION IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE
7. T.10.8 THE EFFECTS OF HIGH AMYLOSE PRODUCTS ON SYMPTOMS AND GUT MICROBIOTA COMPOSITION IN IRRITABLE BOWEL SYNDROME WITH PREDOMINANT CONSTIPATION (IBS-C)
8. Proteomics boosts translational and clinical microbiology
9. T.04.9 ROLE OF DIETARY HABITS ON SYMPTOM CONTROL AND GUT MICROBIOTA COMPOSITION IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
10. T.04.6 REDUCED ADHERENCE TO MEDITERRANEAN DIET AND INTESTINAL MICROBIOTA COMPOSITION IN INFLAMMATORY BOWEL DISEASE PATIENTS
11. P115 Escherichia coli Nissle 1917 modulate gut microbiota composition in ulcerative colitis patients
12. Urinary 1H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment
13. Choice of Next-Generation Sequencing Pipelines
14. Proteomic Profile in Children and Young Adult Patients with Pulmonary Hypertension Due to Complex Congenital Heart Disease: An Observational Cohort Study
15. Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug
16. T05.02.11 SERUM DIAMINOXIDASE LEVELS IN IRRITABLE BOWEL SYNDROME PATIENTS COMPARED TO HEALTHY CONTROLS
17. T02.02.17 CORRELATION BETWEEN DIETARY HABITS AND FECAL MICROBIOTA COMPOSITION IN IRRITABLE BOWEL SYNDROME PATIENTS
18. OC.03.2: HUMAN EXTRACHROMOSOMAL CIRCULAR DNA IS ANEMERGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE.
19. Proteomic and genomic approaches to understanding the 'power plant' of Cryptosporidium .
20. MALDI-TOF MS PROTEOMIC PHENOTYPING BOOSTS CF PATIENT-TAILORED PROTOCOLS IN DIAGNOSTIC MICOLOGY: 327
21. THE GUT MICROBIOTA IN CYSTIC FIBROSIS: A COMPLEX COMMUNITY UNVEILED BY META-OMICS APPROACHES: 326
22. MALDI-TOF for identification of yeasts and fungi: S537
23. Accidental Nasal Myiasis Caused by Megaselia rufipes (Diptera: Phoridae) in a Child
24. Pseudobactin biogenesis in the plant growth-promoting rhizobacterium Pseudomonas strain B10: identification and functional analysis of the L-ornithine N(sup)5-oxygenase (psbA) gene
25. DIAGNOSTIC APPLICATIONS OF MALDI-TOF TECHNIQUE IN THE LABORATORY OF CLINICAL MICROBIOLOGY
26. Dysbiosis, gut microbiota modulation and intestinal permeability in recurrent cystitis patients and concomitant gastrointestinal pathologies
27. Characterization of a mitochondrion-like organelle in Cryptosporidium parvum
28. Cystic fibrosis linked functional impairment and gut microbiota signatures: from omics data to clinical cue
29. Fecal Microbiota Transplant in Two Ulcerative Colitis Pediatric Cases: Gut Microbiota and Clinical Course Correlations
30. Challenging diagnosis of congenital malaria in non-endemic areas 11 Medical and Health Sciences 1108 Medical Microbiology
31. Prediction of inactive disease in juvenile idiopathic arthritis: A multicentre observational cohort study
32. OC.05.5 ALTERATION IN THE ABUNDANCE OF AKKERMANSIA MUCINIPHILA IS ASSOCIATED TO GASTROINTESTINAL AND EXTRA-INTESTINAL DISEASES: TOWARDS THE IDENTIFICATION OF SPECIFIC MICROBIAL SIGNATURES OF DISEASE
33. OC.04.6 FECAL AND MUCOSAL MICROBIOTA PROFILING IN IRRITABLE BOWEL SYNDROME AND INFLAMMATORY BOWEL DISEASE: A FOCUS ON AKKERMANSIA MUCINIPHILA
34. OC.04.5 IL-33/ST2 LEVELS AND GUT MICROBIOTA CHARACTERIZATION CAN PREDICT MUCOSAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS
35. P497 IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis
36. P107 Proteomics in the age of precautionary labeling: a translational approach to food allergy
37. Yeasts from organic or biodynamic grapes: genomic and proteomic identification
38. Proceedings of the 2017 WAO Symposium on Hot Topics in Allergy: Pediatric & Regulatory Aspects: Rome, Italy/Vatican City. 27-29 April 2017
39. Bifidobacterium longum and breve try to modulate microbiota of infants: A new approach to food allergy?
40. Accidental Nasal Myiasis Caused by Megaselia rufipes(Diptera: Phoridae) in a Child
41. Gut Microbiota Dysbiosis as Risk and Premorbid Factors of IBD and IBS Along the Childhood-Adulthood Transition
42. 168 Loss of CFTR function drives the host-gut microbiota interaction: from omics data to clinical cue
43. OC.14.6: Escherichia Coli Nissle 1917 Modulate GUT Microbiota Composition in Ulcerative Colitis Patients
44. P.05.7: Looking for the Most Useful Taxa as Microbial Biomarkers to Decipher IBD Microbiota: A Pilot Study
45. P295 Bifidobacterium longum & breve colonize and persist in microflora of infants with food allergy
46. The putative role of gut microbiota in primary sclerosing cholangitis and ulcerative colitis in children
47. The gut microbiota in cystic fibrosis: a complex community unveiled by meta-omics approaches'
48. Mouse gut enterotypes identified by metaproteomics: a model for neonatal gut microbiota
49. A metaproteomic algorithm to identify gut phylotypes in mouse
50. Design of a bioinformatics algorithm for the assessment of mouse gut phylotypes identified by metaproteomic approach
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.